Adding Cadonilimab to First-Line Standard Chemotherapy Significantly Improves PFS and OS in Patients with Persistent, Recurrent, or Metastatic Cervical Cancer By Ogkologos - November 15, 2024 647 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the COMPASSION-16 study Source RELATED ARTICLESMORE FROM AUTHOR Combination of mFOLFOX6/Bevacizumab Plus Atezolizumab Prolongs PFS Compared with Atezolizumab in First-Line Treatment of dMMR/MSI-H mCRC Use of YEARS Algorithm, D-dimer Levels, and Performing Risk-Dependent CT Pulmonary Angiography is Safe in Patients with Cancer and Suspected Pulmonary Embolism EMA Recommends Extension of Indications for Ponatinib Associated with a New Pharmaceutical Form and a New Strength MOST POPULAR 2022 ASCO Annual Meeting: Advances in Treating Breast Cancer, Colorectal Cancer, Ewing... June 5, 2022 Whole- and Partial-Breast Radiation Effective at Preventing Breast Cancer from Returning December 19, 2018 Neoadjuvant Pertuzumab/Trastuzumab Demonstrates Long-Term Cardiac Safety in HER2-Positive Breast Cancer May 7, 2021 FDA Approves BCMA-Targeted CAR T-Cell Therapy for Multiple Myeloma April 14, 2021 Load more HOT NEWS Adding Tafasitamab and Lenalidomide to R-CHOP Improves PFS in Patients with... Molecular Profiling with Targeted Panel Tests that Includes Fusion Detection Has... WHO’s plans to create a ‘cervical cancer-free future’ Sacituzumab Govitecan Demonstrates Significant Improvement in Survival in Heavily Pretreated, Locally...
